Generic Name: panobinostat

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Chemotherapy Medications

Company: Novartis

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Farydak is an HDAC inhibitor approved for multiple myeloma, in combination with dexamethasone and Velcade (bortezomib).

General Info

Farydak is a histone deacetylase (HDAC) inhibitor that disables an enzyme that keeps DNA tightly coiled. It works by activating genes that halt cancer cell growth.

Clinical trials showed that Farydak in combination with other medications slows progression of multiple myeloma.


Dosing Info:

Farydak is a pill taken every other day for two weeks followed by a week off. It is usually given for eight cycles, but may be continued in people with ongoing clinical benefit.

Side Effects

Common side effects include diarrhea, fatigue, nausea, swelling, decreased appetite, fever and vomiting. It can cause depletion of red blood cells (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Potential severe side effects include heart rhythm abnormalities and heart attack.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: September 18, 2018